A detailed history of Manufacturers Life Insurance Company, The transactions in Ocugen, Inc. stock. As of the latest transaction made, Manufacturers Life Insurance Company, The holds 104,274 shares of OCGN stock, worth $93,846. This represents 0.0% of its overall portfolio holdings.

Number of Shares
104,274
Previous 106,823 2.39%
Holding current value
$93,846
Previous $165,000 37.58%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$0.98 - $1.95 $2,498 - $4,970
-2,549 Reduced 2.39%
104,274 $103,000
Q2 2024

Aug 14, 2024

BUY
$1.18 - $1.98 $126,051 - $211,509
106,823 New
106,823 $165,000
Q2 2023

Aug 11, 2023

SELL
$0.45 - $0.88 $39,002 - $76,272
-86,673 Closed
0 $0
Q4 2022

Aug 11, 2023

BUY
$1.11 - $1.87 $545 - $918
491 Added 0.57%
86,673 $112,000
Q4 2022

Feb 13, 2023

BUY
$1.11 - $1.87 $545 - $918
491 Added 0.57%
86,673 $112,000
Q3 2022

Aug 11, 2023

SELL
$1.75 - $3.1 $3,620 - $6,413
-2,069 Reduced 2.34%
86,182 $153,000
Q3 2022

Nov 03, 2022

SELL
$1.75 - $3.1 $3,620 - $6,413
-2,069 Reduced 2.34%
86,182 $153,000
Q2 2022

Aug 11, 2023

BUY
$1.83 - $3.45 $23,275 - $43,880
12,719 Added 16.84%
88,251 $200,000
Q2 2022

Aug 15, 2022

BUY
$1.83 - $3.45 $23,275 - $43,880
12,719 Added 16.84%
88,251 $200,000
Q1 2022

Aug 11, 2023

SELL
$2.34 - $4.72 $26,069 - $52,585
-11,141 Reduced 12.85%
75,532 $249,000
Q1 2022

May 20, 2022

SELL
$2.34 - $4.72 $43,521 - $87,787
-18,599 Reduced 19.76%
75,532 $249,000
Q4 2021

Feb 16, 2022

SELL
$4.38 - $15.67 $4,752 - $17,001
-1,085 Reduced 1.14%
94,131 $428,000
Q3 2021

Nov 12, 2021

SELL
$6.36 - $8.51 $45,715 - $61,169
-7,188 Reduced 7.02%
95,216 $684,000
Q2 2021

Aug 12, 2021

BUY
$5.52 - $15.68 $565,270 - $1.61 Million
102,404 New
102,404 $822,000

Others Institutions Holding OCGN

About Ocugen, Inc.


  • Ticker OCGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 216,566,000
  • Market Cap $195M
  • Description
  • Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmento...
More about OCGN
Track This Portfolio

Track Manufacturers Life Insurance Company, The Portfolio

Follow Manufacturers Life Insurance Company, The and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Manufacturers Life Insurance Company, The, based on Form 13F filings with the SEC.

News

Stay updated on Manufacturers Life Insurance Company, The with notifications on news.